 |
 |
 |
|
|
 |
 |
|
 |
2010-11 Membership Guide
|
Membership News
|
The State of American Business 2010
|
|
|
|
|
|
|
|
|
Please visit our Nordic sister organizations:
|
|
|
|
|
|
|
|
|
|
News
|
|
| |
|
| Europe's Oncology Community Meets at ECCP 2010 in Oslo September 15-17 |
Europe's most promising oncology biotechs and other key stakeholders will gather in Oslo, Norway, September 15-17 for the 2nd European Cancer Cluster Meeting (ECCP 2010). Co-hosted by the Oslo Cancer Cluster and the Cancer-Bio-Sante Cluster from Toulouse, the two-day meeting is a unique partnering opportunity for oncology biotech companies, business development and licensing executives from the pharmaceutical industry and investors, as well as innovative researchers and clinicians.
Partnering is the overall theme. The two opening sessions will focus on Oncology 2020 and give an outlook for the decade ahead and discuss new models for collaboration between academia and industry to drive innovation. Building on that, a roundtable will discuss how a ''global bioscience gateway'' involving partners from the US, Europe and China can accelerate the development of new cancer diagnostics and medicines.
In addition, meeting sessions will address important aspects of oncology including the role of biomarkers in personalised medicine, the need for cancer-focussed clinical trial networks and ways to adapt to the financing/partnering climate.
Bjarte Reve, CEO of the Oslo Cancer Cluster aims to build on the success of last year's inaugural conference which attracted some 263 companies from 23 countries: ''Treatment and survival rates for cancer continue to improve and we believe ECCP provides the perfect forum for the oncology community to meet and find ways to further accelerate the development and uptake of new diagnostics and treatments.''
|
Date posted: 16th of June 2010
Source: Oslo Cancer Cluster
News Category: Health
|
| Back |
|
© 2010 American Chamber of Commerce in Norway. All rights reserved.
|
|
|
|
|
|
|
|
|
|
American Chamber Patron Member
|
|
|
|
|
|
|
|
|
|
|
